A critical assessment of dose effects of post‐thaw CD34 on autologous stem cell transplantation treatment of haematological malignancies

[1]  G. Salton,et al.  Non‐cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma , 2022, Transfusion.

[2]  O. Valero,et al.  Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation , 2022, Bone Marrow Transplantation.

[3]  J. D. du Toit,et al.  Predictors of poor haematopoietic stem cell mobilisation in patients with haematological malignancies at a South African centre. , 2022, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[4]  A. Belisário,et al.  Influence of laboratory procedures on postthawing cell viability and hematopoietic engraftment after autologous peripheral blood stem cell transplantation , 2021, Transfusion.

[5]  Andrea Lius,et al.  Effect of high nucleated cell concentration on product viability and hematopoietic recovery in autologous transplantation , 2020, Transfusion.

[6]  P. Jeyaraman,et al.  Adequate Engraftment With Lower Hematopoietic Stem Cell Dose. , 2020, Clinical lymphoma, myeloma & leukemia.

[7]  Chutima Kunacheewa,et al.  Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis , 2018, BMC Cancer.

[8]  D. Linch,et al.  Optimisation and quality control of cell processing for autologous stem cell transplantation , 2016, British journal of haematology.

[9]  J. Vose,et al.  Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  J. Stapleton,et al.  Pre infusion, post thaw CD34+ peripheral blood stem cell enumeration as a predictor of haematopoietic engraftment in autologous haematopoietic cell transplantation. , 2014, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[11]  M. Greenwood,et al.  Factors predicting haematopoietic recovery in patients undergoing autologous transplantation: 11-year experience from a single centre , 2014, Annals of Hematology.

[12]  J. Dipersio,et al.  Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  J. Vose,et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  L. Gordon,et al.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  E. Ball,et al.  Optimal use of G-CSF administration after hematopoietic SCT , 2009, Bone Marrow Transplantation.

[16]  H. Kim,et al.  Post‐thaw viable CD34+ cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation , 2007, Vox sanguinis.

[17]  L. Larratt,et al.  Association of post-thaw viable CD34+ cells and CFU-GM with time to hematopoietic engraftment , 2005, Bone Marrow Transplantation.

[18]  T. Wentzel‐Larsen,et al.  Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg. , 2004, Cytotherapy.

[19]  M. Bhatia,et al.  Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.

[20]  Â. Maiolino,et al.  A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation , 2002, Bone Marrow Transplantation.